Genevieve E Martin1, John Frater1,2. 1. Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research. 2. Oxford National Institute of Health Research Biomedical Research Centre, Oxford, UK.
Abstract
PURPOSE OF REVIEW: The aim of the current review is to explore the evidence around virological remission in ART-treated and untreated individuals living with HIV. With increasing evidence and interest in post-treatment control within the HIV-cure field, it is now increasingly important to agree on definitions to allow different 'controller' phenotypes to be clearly distinguished and mechanisms compared. RECENT FINDINGS: This review explores recent data on potential predictors and mechanisms driving spontaneous and post-treatment control. We explore data on the role of the reservoir as a determinant of control and the challenges associated with its study, including the safety of treatment interruption. We explore options around deriving a consensus on how to define different forms of control and the longer term utility of achieving remission. SUMMARY: Post-treatment control and remission following treatment interruption are becoming increasingly common measures of intervention efficacy in cure trials. As well as a need to show treatment interruption protocols are well tolerated and acceptable, for these measures to be robust and comparable between studies, clear and consensual definitions need to be agreed.
PURPOSE OF REVIEW: The aim of the current review is to explore the evidence around virological remission in ART-treated and untreated individuals living with HIV. With increasing evidence and interest in post-treatment control within the HIV-cure field, it is now increasingly important to agree on definitions to allow different 'controller' phenotypes to be clearly distinguished and mechanisms compared. RECENT FINDINGS: This review explores recent data on potential predictors and mechanisms driving spontaneous and post-treatment control. We explore data on the role of the reservoir as a determinant of control and the challenges associated with its study, including the safety of treatment interruption. We explore options around deriving a consensus on how to define different forms of control and the longer term utility of achieving remission. SUMMARY: Post-treatment control and remission following treatment interruption are becoming increasingly common measures of intervention efficacy in cure trials. As well as a need to show treatment interruption protocols are well tolerated and acceptable, for these measures to be robust and comparable between studies, clear and consensual definitions need to be agreed.
Authors: Ari Bitnun; Doris G Ransy; Jason Brophy; Fatima Kakkar; Michael Hawkes; Lindy Samson; Bayader Annabi; Amélie Pagliuzza; Jacob-Adams Morand; Laura Sauve; Nicolas Chomont; Stephanie Lavoie; John Kim; Paul Sandstrom; Paul A Wender; Terry Lee; Joel Singer; Stanley E Read; Hugo Soudeyns Journal: Clin Infect Dis Date: 2020-02-14 Impact factor: 9.079
Authors: Alexander O Pasternak; Marlous L Grijsen; Ferdinand W Wit; Margreet Bakker; Suzanne Jurriaans; Jan M Prins; Ben Berkhout Journal: JCI Insight Date: 2020-03-26
Authors: Matthew A Spinelli; Warren C Rodrigues; Guohong Wang; Michael Vincent; David V Glidden; Hideaki Okochi; Randy Stalter; Patricia Defechereux; Madeline Deutsch; Robert M Grant; Kenneth Ngure; Nelly R Mugo; Jared M Baeten; Monica Gandhi Journal: J Acquir Immune Defic Syndr Date: 2020-06-01 Impact factor: 3.771
Authors: Christina K Psomas; Sarah Fidler; Malcolm Macartney; Richard Jeffreys; Lisa Reilly; Simon Collins; Santiago Moreno; Jean-Pierre Routy; Alexander Pasternak; Sabine Kinloch-de Loës Journal: J Virus Erad Date: 2018-10-01
Authors: Marta Calvet-Mirabent; Ildefonso Sánchez-Cerrillo; Noa Martín-Cófreces; Pedro Martínez-Fleta; Hortensia de la Fuente; Ilya Tsukalov; Cristina Delgado-Arévalo; María José Calzada; Ignacio de Los Santos; Jesús Sanz; Lucio García-Fraile; Francisco Sánchez-Madrid; Arantzazu Alfranca; María Ángeles Muñoz-Fernández; Maria J Buzón; Enrique Martín-Gayo Journal: EBioMedicine Date: 2022-06-02 Impact factor: 11.205